[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE493980T1 - Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung - Google Patents

Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung

Info

Publication number
ATE493980T1
ATE493980T1 AT03783726T AT03783726T ATE493980T1 AT E493980 T1 ATE493980 T1 AT E493980T1 AT 03783726 T AT03783726 T AT 03783726T AT 03783726 T AT03783726 T AT 03783726T AT E493980 T1 ATE493980 T1 AT E493980T1
Authority
AT
Austria
Prior art keywords
transplant rejection
chronic transplant
prevent chronic
diamide derivative
subject
Prior art date
Application number
AT03783726T
Other languages
English (en)
Inventor
John Williams
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE493980T1 publication Critical patent/ATE493980T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03783726T 2002-11-21 2003-11-21 Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung ATE493980T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42833202P 2002-11-21 2002-11-21
PCT/US2003/037318 WO2004047825A1 (en) 2002-11-21 2003-11-21 Use of diamide derivatives for inhibiting chronic tissue transplant rejection

Publications (1)

Publication Number Publication Date
ATE493980T1 true ATE493980T1 (de) 2011-01-15

Family

ID=32393386

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03783726T ATE493980T1 (de) 2002-11-21 2003-11-21 Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung

Country Status (9)

Country Link
US (2) US7687530B2 (de)
EP (1) EP1567138B1 (de)
JP (2) JP4928079B2 (de)
AT (1) ATE493980T1 (de)
AU (1) AU2003291134A1 (de)
DE (1) DE60335652D1 (de)
ES (1) ES2363914T3 (de)
PT (1) PT1567138E (de)
WO (1) WO2004047825A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0111158A (pt) * 2000-05-12 2004-04-06 Genzyme Corp Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente
ATE520400T1 (de) * 2002-11-21 2011-09-15 Genzyme Corp Kombination von einem diamidderivat und immunsuppressiva zur unterdrückung der transplantatabstossung
ES2363914T3 (es) * 2002-11-21 2011-08-19 Genzyme Corporation Utilización de un derivado de diamida para inhibir el rechazo crónico de un transplante.
CA2957704A1 (en) 2004-01-21 2005-08-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining a graft tolerant phenotype in a subject
JP2008537875A (ja) 2005-03-14 2008-10-02 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 固形臓器移植レシピエントにおいて移植片生着を評価するための方法および組成物
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
EP2324129A4 (de) 2008-08-18 2012-06-20 Univ Leland Stanford Junior Verfahren und zusammensetzungen zur bestimmung eines transplantattoleranten phänotyps bei einer person
EP2387618B1 (de) 2009-01-15 2014-05-21 The Board of Trustees of The Leland Stanford Junior University Biomarker-tafel zur diagnose und vorhersage von transplantatabstossung
WO2011068829A1 (en) 2009-12-02 2011-06-09 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for determining an allograft tolerant phenotype
EP2803735B1 (de) 2010-03-25 2020-03-25 The Board of Trustees of the Leland Stanford Junior University Protein- und Gen-Biomarker für die Abstoßung von Organtransplantationen
WO2012139051A2 (en) 2011-04-06 2012-10-11 The Board Of Trustees Of The Leland Stanford Junior University Autoantibody biomarkers for iga nephropathy
US20150038541A1 (en) * 2012-03-19 2015-02-05 Aposignal Bioscience Llc Composition and methods for cell modulation
WO2017142879A1 (en) * 2016-02-16 2017-08-24 The Regents Of The University Of California Methods for immune system modulation with microporous annealed particle gels

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4944796A (en) * 1988-11-14 1990-07-31 Ici Americas Inc. Certain 2-(disubstituted amino) acetanilide herbicides
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
US6420374B1 (en) * 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
US5861382A (en) * 1992-05-01 1999-01-19 Yeda Research And Development Co. Ltd. Methods for regulation of active TNF-α
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
EP0663836B1 (de) 1992-10-08 1997-07-09 The Kennedy Institute Of Rheumatology Behandlung von autoimmun- und entzundungskrankheiten
US6030615A (en) * 1993-05-17 2000-02-29 The Picower Institute For Medical Research Combination method for treating diseases caused by cytokine-mediated toxicity
JPH09510952A (ja) 1993-10-06 1997-11-04 ザ ケネディー インスティチュート オブ リューマトロジー 自己免疫疾患および炎症性疾患の治療
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
DE4430128A1 (de) * 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
DE4430127A1 (de) * 1994-08-25 1996-03-14 Hoechst Ag Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
US5932737A (en) * 1994-12-02 1999-08-03 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds for treatment of no-mediated diseases
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
FR2730411B1 (fr) * 1995-02-14 1997-03-28 Centre Nat Rech Scient Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
US5654312A (en) * 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
ATE259235T1 (de) 1995-07-20 2004-02-15 Cell Eng Ag Zubereitung enthaltend glykane übereinstimmend mit transferrin glykaner als aktives prinzip für die induktion der immuntoleranz gegen antigene
IL115245A (en) * 1995-09-11 2002-12-01 Yissum Res Dev Co Tumor necrosis factor inhibiting pharmaceuticals
PL326710A1 (en) * 1995-11-22 1998-10-26 Darwin Discovery Ltd Mercaptoalkylpeptidic compounds having an imidazolic substituent and their application as inhibitors of intercellular substance metaloproteinases and/or of tumor necrosis factor (tnf)
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6211160B1 (en) * 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
PT942740E (pt) * 1996-12-06 2004-01-30 Amgen Inc Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
AU5623398A (en) 1997-03-07 1998-09-22 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
US5801193A (en) * 1997-04-15 1998-09-01 Immune Modulation, Inc. Compositions and methods for immunosuppressing
US6506569B1 (en) * 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
US6503184B1 (en) * 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US6229878B1 (en) * 1998-01-21 2001-05-08 Lucent Technologies, Inc. Telephone answering method and apparatus
US6359061B1 (en) * 1999-03-19 2002-03-19 Isis Pharmaceuticals, Inc. Amide compound libraries
EP1165500A1 (de) * 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Amidderivate als inhibitoren von matrix metalloproteinasen, tnf-alpha und aggrecanase
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
AU1590201A (en) 1999-11-09 2001-06-06 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
BR0111158A (pt) * 2000-05-12 2004-04-06 Genzyme Corp Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente
JP2003534327A (ja) * 2000-05-22 2003-11-18 レオ・ファーマ・アクティーゼルスカブ ＩＬ−１βおよびＴＮＦ−αの抑制剤としてのベンゾフェノン
AU2003280429A1 (en) * 2002-06-26 2004-01-19 The Trustees Of Columbia Uninersity In The City Of New York Use of streptavidin to inhibit transplant rejection
ATE520400T1 (de) * 2002-11-21 2011-09-15 Genzyme Corp Kombination von einem diamidderivat und immunsuppressiva zur unterdrückung der transplantatabstossung
ES2363914T3 (es) * 2002-11-21 2011-08-19 Genzyme Corporation Utilización de un derivado de diamida para inhibir el rechazo crónico de un transplante.

Also Published As

Publication number Publication date
JP4928079B2 (ja) 2012-05-09
PT1567138E (pt) 2011-04-11
AU2003291134A1 (en) 2004-06-18
DE60335652D1 (de) 2011-02-17
US20040163654A1 (en) 2004-08-26
EP1567138B1 (de) 2011-01-05
JP2006514013A (ja) 2006-04-27
JP2010280725A (ja) 2010-12-16
WO2004047825A1 (en) 2004-06-10
ES2363914T3 (es) 2011-08-19
US20100256211A1 (en) 2010-10-07
EP1567138A1 (de) 2005-08-31
US7687530B2 (en) 2010-03-30

Similar Documents

Publication Publication Date Title
ATE493980T1 (de) Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
ATE534377T1 (de) Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen
ATE447948T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
ATE556711T1 (de) Verfahren zur verbesserung der hautqualität
SE0301886D0 (sv) New use V
ATE514435T1 (de) Verwendung eines dpp-iv-hemmers zur minderung hypoglykämischer ereignisse
DE602007006419D1 (de) Verfahren zur verwendung von guava-extrakt und zusammensetzung mit guava-extrakt
MX2009011823A (es) Piridonacarboxamidas, agentes protectores de plantas utiles que contienen a estas y procedimientos para su preparacion y su utilizacion.
ATE464895T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen
DE602004012079D1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
ATE369845T1 (de) Behandlung der nebenwirkungen von statinen
SE0301888D0 (sv) New use VII
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
MX2009002919A (es) Derivados de azetidina y azetidona utiles en el tratamiento del dolor y trastornos del metabolismo de los lipidos.
DE60316672D1 (de) Polycyclische verbindungen als potenten alpha2-adrenoceptor antagonisten
EA200900939A1 (ru) Фунгицидные смеси из анилидов 1-метилпиразол-4-илкарбоновой кислоты и азолопиримидиниламинов
RS51190B (sr) Aminoacilni derivati kao prolekovi i lekovi za lečenje tromboembolijskih bolesti
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE444749T1 (de) Benzothiazolium verbindungen zur verwendung in methoden zur hemmung der no produktion und von tnf alpha und zur behandlung von coronavirus infektionen
DE69822626D1 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
ATE208144T1 (de) Verfahren und zusammensetzungen zur steigerung der anaerobe leistungsfähigkeit in geweben
TW200600084A (en) Anti-coronavirus compounds
WO2006002763A3 (de) Substituierte tetrahydroisochinoline als mmp-inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
SE0301885D0 (sv) New use IV

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties